Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy? Surg Oncol Clin N Am 2018 Jan;27(1):141-153

Date

11/15/2017

Pubmed ID

29132557

DOI

10.1016/j.soc.2017.08.004

Scopus ID

2-s2.0-85034238097 (requires institutional sign-in at Scopus site)   101 Citations

Abstract

Progress in the treatment of triple-negative breast cancer remains an important challenge. Given the aggressive biology and high risk of distant recurrence, systemic chemotherapy is warranted in most patients. Neaodjuvant chemotherapy benefits patients with locally advanced disease by downsizing the tumor and increasing the probability of breast-conserving surgery. Clinical and pathologic responses provide important prognostic information, which makes neoadjuvant therapy an attractive approach for all patients with triple-negative breast cancer. Clinical research in the neoadjuvant setting is focused on improvement in pathologic complete response rates and outcomes of patients with residual disease.

Author List

Chaudhary LN, Wilkinson KH, Kong A

Authors

Lubna N. Chaudhary MD Associate Professor in the Medicine department at Medical College of Wisconsin
Amanda L. Kong MD, MS Professor in the Surgery department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Antineoplastic Agents
Chemotherapy, Adjuvant
Female
Humans
Neoadjuvant Therapy
Triple Negative Breast Neoplasms